Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
MTX-COVAB by Memo Therapeutics for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
MTX-COVAB is under clinical development by Memo Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to...
Data Insights
MTX-COVAB by Memo Therapeutics for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
MTX-COVAB is under clinical development by Memo Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to...